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Many recent studies have confirmed older observations and the clinical suspicion that psoriasis patients are 
more likely to have unhealthy lifestyles and 
psychological impairment and to suffer from 
obesity, hypertension, hyperlipidemia, and dia-
betes. In the past five years, investigators—some 
with close ties to the makers of biologics—have 
advanced the hypothesis that these observed 
associations reflect psoriasis-related inflamma-
tion, which in turn induces development of these 
comorbidities, including metabolic syndrome 
and cardiovascular disease. We agree that pso-
riasis is associated with several comorbidities, 
but this relationship is complex and the level of 
evidence supporting a pathogenic relationship is 
low. The hypothesis that psoriasis is a systemic 
disease is tempting and, if accepted, has major 
implications for its management. Before we 
accept this hypothesis, we need evidence from 
independent prospective cohort studies and 
adequately powered controlled trials rather than 
associations gleaned from databases designed 
for different purposes. Moreover, current evi-
dence indicates that using biologics is not the 
safest or most cost-effective approach to reduc-
ing cardiovascular disease and its complications 
in patients with psoriasis. Ideally, optimal care of 
these patients requires careful attention to their 
medical and psychological needs.
That psoriasis is a chronic and sometimes 
disabling disease associated with a substantial 
burden on those severely affected, and that it is 
associated with a higher risk of obesity, smok-
ing, and the myriad medical conditions associ-
ated with depression and poor body self-image, 
has been known to clinicians for decades. 
Nearly 40 years ago, McDonald and Calabresi 
(1973) hypothesized the existence of an asso-
ciation between psoriasis and vascular disease. 
Based on their study of patients hospitalized 
for psoriasis (i.e., treatment was used to define 
severity), they observed a higher risk of occlu-
sive vascular events in patients with “severe” 
psoriasis (McDonald and Calabresi, 1978). In 
2006, Gelfand et al., drawing on data from a UK 
general-practice research database, found an 
increased risk of myocardial infarction in those 
with severe psoriasis, also defined by treatment 
(Gelfand et al., 2006a). Since 2006, more than 
300 papers concerning an association between 
psoriasis and vascular disease risk factors have 
been published. Many of these studies share a 
common theme: more severe psoriasis is associ-
ated with a higher prevalence of risk factors for 
cardiovascular (CV) disease. Importantly, many 
of these studies were sponsored by makers of 
biologics or authored by those with close finan-
cial relationships to these companies.
The work by Langan et al. published in this 
issue uses metabolic syndrome as its end point 
in another associative study. The investigators 
analyzed data from a UK primary-care medical 
records database. That metabolic syndrome is 
more frequent in those who seek care for severe 
psoriasis is not surprising. Metabolic syndrome is 
basically a composite measure based on obesity, 
hyperglycemia, and abnormalities of choles-
terol, triglycerides, and hypertension, conditions 
known to appear together and to appear more 
frequently in those with more severe psoriasis. 
It is undoubtedly a true association. Our earlier 
commentaries on this subject pointed out the 
complexity of the relationships between psoriasis 
and comorbidity for CV disease as well as some 
of the potential biases of studies based on data of 
the type that Langan and many others have relied 
on (Nijsten and Wakkee, 2009; Stern, 2010). 
Furthermore, whether metabolic syndrome prog-
nostic values exceed those of their individual 
components taken together is still debated (Sattar 
et al., 2008; Motillo et al., 2010).
We believe that there is abundant evidence 
that severe psoriasis greatly affects individu-
als and is likely to be associated with states of 
mind, habits, and habitus that are risk factors for 
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CV disease. However, what is uncertain is the hypothesis that 
the biologic mechanism responsible for increased risk of CV 
disease is, at least in part, a proinflammatory state associated 
with severe psoriasis, as has been hypothesized for rheuma-
toid arthritis (Gelfand et al., 2006a; Boehncke et al., 2010; 
Davidovici et al., 2010). In contrast to rheumatoid arthritis, 
psoriasis is not a systemic disease with multiorgan involve-
ment (except joints); there is no serological immunological 
marker for psoriasis; and evidence of an increased inflamma-
tory state (e.g., increased C-reactive protein or tumor necro-
sis factor-α levels) is inconsistent and does not show a clear 
dose–response relationship, raising further doubt about this 
inflammation hypothesis.
The implications of this hypothetical “psoriatic march” 
(Boehncke et al., 2010) are both medically and economically 
important. If the increased risk of CV disease, including meta-
bolic syndrome, is a result of psoriasis-associated inflamma-
tion, then an additional benefit of anti-inflammatory therapies 
such as the biologics might be a decrease in CV risk. Studies 
addressing this additional treatment benefit are few, but a large 
claims database study observed a slightly higher, although 
not significant, risk of CV disease for patients receiving sys-
temic therapy as compared with those receiving phototherapy 
(Abuabara et al., 2011). After adjustment for surveillance bias, 
psoriasis patients with prior exposure to systemic drugs had 
a comparable risk of developing components of the meta-
bolic syndrome or acute myocardial infarction (Wakkee et 
al., 2009, 2010). Even if biologics do reduce CV disease risk, 
which seems unlikely, their annual cost is about $25,000 per 
year per patient. Treatment with statins and blood pressure 
medicine purchased from discount pharmacies costs less than 
$100 per year and has been proven to reduce CV disease and 
mortality only in high-risk individuals (http://walmart.com/
cp/1078664, accessed 24 October 2011).
The indication for treating psoriasis with biological agents 
should remain severe psoriasis for which treatments with 
established benefits and risks in long-term use are not ade-
quate. The use of biologics on a hoped-for reduction in CV 
disease cannot currently be defended—from scientific, soci-
etal, or medical perspectives—because it fails to take into 
account the associated risks and cost of the biologics. If such 
a rationale for using biologics is to be considered, the level 
of evidence must increase substantially. However, a random-
ized control trial to study the effect of biologics on CV risk 
in patients with severe psoriasis already receiving the usual 
therapy to reduce CV risk (blood pressure control, diet, etc.) 
is impractical, probably infeasible, and perhaps not ethical, 
given our lack of knowledge about their long-term safety. 
Before considering trials to determine whether treating pso-
riasis with biologics reduces CV risk, the long-term safety 
and efficacy of these agents, both absolutely and relative to 
methotrexate and phototherapy, should be determined.
Many of the studies that link psoriasis to other diseases 
have been sponsored by the pharmaceutical industry. It 
seems to us that the comorbidities that are most interest-
ing to these sponsors and their consultants are those that 
upgrade the severity of psoriasis and/or overlap with 
adverse events of their drugs. By showing that psoriasis 
increases the risk of life-threatening conditions such as 
CV disease and lymphoma, psoriasis is upgraded from a 
chronic, non-life-threatening disease to a life-threatening 
systemic disease that may require more aggressive and con-
tinuous therapy (Gelfand et al., 2006a, b). However, long-
term use of immunosuppressive drugs may increase the risk 
of malignancy (such as lymphoma) and infection. In addi-
tion, the tumor necrosis factor antagonists are contraindi-
cated in patients with moderate to severe heart failure. A 
recent study in JAMA showed a nearly significant increase 
in major adverse CV events among short-term users of inter-
leukin-12/13 inhibitors who were included in randomized 
clinical trials (Ryan et al., 2011). Briakinumab was with-
drawn from consideration for approval by the US Food 
and Drug Administration, presumably on the basis of these 
data (http://www.modernmedicine.com/modernmedicine/
article/articleDetail.jsp?id=737486, accessed January 11, 
2012). Hence, it would not appear to be in the interest of 
patients to conclude that severe psoriasis is a risk factor for 
CV disease and lymphoma. If these notions were accepted 
on face value, such events might be attributed to the disease 
rather than, more correctly, to the therapy itself. We hasten 
to add that neither we nor anyone else has the answer to 
this dilemma.
Dermatology must advance beyond the “circumstantial 
evidence” of association studies based on administrative 
databases to prospective cohort studies designed to test spe-
cific hypotheses. As previously noted, the makers of biolog-
ics all pledged to perform large long-term cohort and other 
safety studies. Now, nearly a decade after the first biologic 
was approved for psoriasis, not even enrollment figures are 
available for these studies. We would argue that these com-
panies, which sell billions of dollars each year of biologic 
agents for the treatment of psoriasis, should honor their com-
mitment to performing phase IV safety studies (Stern and 
Nijsten, 2004). These studies must be adequately financed 
and executed by individuals who are academically based 
and financially independent from the sponsors. In the mean-
time, clinicians should realize that psoriasis is a burdensome 
disease and that individuals with severe psoriasis are more 
likely to have depression, hypertension, hyperlipidemia, and 
obesity, all risk factors for CV disease. Complete care of these 
patients includes ensuring that they receive optimal medical 
management as well as psychological support.
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